Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors

Erlotinib is a highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor for the targeted therapy of non-small-cell lung cancer (NSCLC) However, the efficacy of erlotinib is limited because the development of drug resistance during chemotherapy. Indoleamine 2,3-dioxyg...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Xi-xi, Gong, Xiao-qing, Mao, Long-fei, Sun, Ge, Yang, Jian-xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399373/
https://www.ncbi.nlm.nih.gov/pubmed/36034879
http://dx.doi.org/10.3389/fphar.2022.940704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399373/
https://www.ncbi.nlm.nih.gov/pubmed/36034879
http://dx.doi.org/10.3389/fphar.2022.940704

Ejemplares similares